Seeing Is Believing
ADAP is currently covered by 4 analysts with an average price target of $2.79. This is a potential upside of $2.52 (933.33%) from yesterday's end of day stock price of $0.27.
Adaptimmune Therapeutics Plc's activity chart (see below) currently has 17 price targets and 22 ratings on display. The stock rating distribution of ADAP is 25% HOLD, 50% BUY and 25% SELL.
Analysts average stock forecasts to be materialized ratio is 39% with an average time for these price targets to be met of 270 days.
Highest price target for ADAP is $2, Lowest price target is $1, average price target is $1.
Most recent stock forecast was given by PETER LAWSON from BARCLAYS on 10-Aug-2023. First documented stock forecast 30-Sep-2016.
3/31/00 2 for 1
Currently out of the existing stock ratings of ADAP, 1 are a HOLD (25%), 2 are a BUY (50%), 1 are a SELL (25%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Sell
$1
$-0.01 (-0.99%)
$4
1 years 8 months 14 days ago
(10-Aug-2023)
3/4 (75%)
$0.18 (21.95%)
245
Buy
$5
$3.99 (395.05%)
2 years 3 months 21 days ago
(03-Jan-2023)
0/2 (0%)
$3.33 (199.40%)
Buy
$9
$8.22 (1053.85%)
$9
2 years 5 months 15 days ago
(09-Nov-2022)
2/3 (66.67%)
$1.29 (98.13%)
340
Hold
$3
$1.99 (197.03%)
2 years 11 months 15 days ago
(09-May-2022)
1/5 (20%)
$1.46 (94.81%)
377
Buy
$6
$5.22 (669.23%)
$16
5 years 11 months 17 days ago
(07-May-2019)
1/3 (33.33%)
$6.36 (92.59%)
388
What is ADAP (Adaptimmune Therapeutics Plc) average time for price targets to be met?
Which analyst has the current highest performing score on ADAP (Adaptimmune Therapeutics Plc) with a proven track record?
Which analyst has the current lower performing score on ADAP (Adaptimmune Therapeutics Plc) with a proven track record?
Which analyst has the most public recommendations on ADAP (Adaptimmune Therapeutics Plc)?
Which analyst is the currently most bullish on ADAP (Adaptimmune Therapeutics Plc)?
Which analyst is the currently most reserved on ADAP (Adaptimmune Therapeutics Plc)?